GSK announces Phase III data for TYKERB/TYVERB® (lapatinib) in combination with chemotherapy for advanced HER2-positive gastric cancer

Issued: Monday 3 June 2013, London UK

GlaxoSmithKline (GSK) plc today announced that its study of TYKERB/TYVERB® (lapatinib) in combination with chemotherapy in patients with HER2-positive advanced gastric cancer did not meet the primary endpoint of improved overall survival (OS) compared to chemotherapy alone. The median OS for patients in the lapatinib plus chemotherapy group was 12.2 months compared to 10.5 months for patients randomised to placebo plus chemotherapy (HR=0.91; 95% CI: 0.73, 1.12; p=0.3492). There were no new safety signals identified in this trial.

This was a randomised, double-blinded Phase III study of lapatinib in combination with chemotherapy (oxaliplatin and capecitabine) compared to chemotherapy plus placebo in patients with HER2-positive advanced gastric cancer in the first line treatment setting. The primary endpoint was overall survival and secondary endpoints included progression-free survival, response rate and duration of response. Median progression-free survival for patients in the lapatinib plus chemotherapy group was 6.0 months and 5.4 months for those in the chemotherapy alone group. Response rate was 53% for patients in the lapatinib plus chemotherapy group and 39% for those in the chemotherapy alone group.  In the lapatinib plus chemotherapy group, the duration of response was 7.3 months compared to 5.6 months in the placebo plus chemotherapy group.

The most commonly reported (≥ 20%) adverse events (AE) in the lapatinib plus chemotherapy group were diarrhoea (58%), nausea (49%), vomiting (44%), decreased appetite (41%), fatigue (24%), rash (21%) and palmar-plantar erythrodysesthesia (20%). The most common AEs in the chemotherapy alone group were nausea (43%), vomiting (36%), decreased appetite (32%), diarrhoea (29%), fatigue (21%) and peripheral neuropathy (20%).  Serious adverse events (SAEs) reported in more than 2% of patients in the lapatinib plus chemotherapy group were diarrhoea (6%), vomiting (3%), anemia (2%), dehydration (2%), nausea (2%). Vomiting (2%) was the most common SAE reported in the chemotherapy group.

TYKERB/TYVERB (lapatinib) is not approved or licensed anywhere in the world for the treatment of HER2-positive advanced gastric cancer.

For full US Prescribing Information for TYKERB (lapatinib) including BOXED WARNING for hepatotoxicity, please visit: http://us.gsk.com/html/medicines/index.html For the EU SPC for TYVERB (lapatinib) in approved indications, please visit http://health.gsk.com/  

About study EGF110656 (NCT00680901)

This was a  global, randomised, multicentre, double-blinded, Phase III study comparing the efficacy and tolerability of lapatinib in combination with oxaliplatin and capecitabine to oxaliplatin, capecitabine and placebo in subjects with HER2-positive advanced gastric (including esophageal and gastro-esophageal junction) cancer in the first line  treatment setting.  GSK collaborated with the TRIO/IDDI (Translational Research in Oncology, TRIO; International Drug Development Institute) cooperative research group to conduct the study. The primary end point of overall survival (OS) was evaluated in the primary efficacy population which was defined as those randomised patients with HER2-positive tumours confirmed by fluorescence in situ hybridisation (FISH) testing conducted by a central laboratory. Secondary endpoints included progression-free survival, response rate, safety and quality of life.

GlaxoSmithKline – one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit www.gsk.com

 

GlaxoSmithKline Enquiries:

 

 

 

UK Media enquiries:

David Mawdsley

+44 (0) 20 8047 5502

(London)

 

Simon Steel

+44 (0) 20 8047 5502

(London)

 

David Daley

+44 (0) 20 8047 5502

(London)

 

Catherine Hartley

+44 (0) 20 8047 5502

(London)

 

 

 

 

US Media enquiries:

Stephen Rea

+1 215 751 4394

(Philadelphia)

 

Melinda Stubbee

+1 919 483 2510

(North Carolina)

 

Anna Padula

+1 215 751 4271

(Philadelphia)

 

Bernadette King

+1 215 751 3632

(Philadelphia)

 

Karen Collins

+1 919 483 2527

(North Carolina)

 

 

 

 

Analyst/Investor enquiries:

Ziba Shamsi

+ 44 (0) 20 8047 3289

(London)

 

Lucy Budd

+44 (0) 20 8047 2248

(London)

 

Tom Curry

+ 1 215 751 5419

(Philadelphia)

 

Gary Davies

+ 44 (0) 20 8047 5503

(London)

 

James Dodwell

+ 44 (0) 20 8047 2406

(London)

 

Jeff McLaughlin

+ 1 215 751 7002

(Philadelphia)

 

Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect GSK' s operations are described under Item 3.D 'Risk factors' in the company's Annual Report on Form 20-F for 2012.

 

This press release is intended for business journalists and analysts/investors. Please note that this release may not have been issued in every market in which GSK operates.